Abstract
In order to study the relationship between erythropoiesis and serum ferritin (SF) during erythropoietin (rHuEPO) therapy in the anaemia of end-stage renal disease (ESRD), 19 patients were followed without iron supplementation and at a fixed dose of the drug (40 U/kg). Twelve patients failed to attain the target haemoglobin (Hb) value, 7 of whom due to the appearance of iron deficiency. Erythropoiesis, as measured by the serum transferrin receptor concentration, increased from 12 to 120% of the basal value. This increment was not constantly associated with a proportional rise of Hb or reticulocyte count. SF decreased exponentially from a median value of 221 μg/dl (range 42-470) to a median value of 54 μg/dl (range 20-172). Halving of the basal SF value (SF-T50) was reached at the 18th-95th day of therapy (median = 43), representing a iron shift of 3.4-11.6 mg/day (median = 5.4). SF-T50 was not correlated with the Hb increase, but with that of erythropoiesis (r = 0.78; p = 0.003). The minimum SF (MSF) value attained was not correlated with the appearance of iron deficiency. The conclusion is that the rate of SF decrease during rHuEPO in ESRD is a reliable measure of iron mobilisation for erythropoiesis, but not for haematologic response. The MSF value reached during therapy is not representative of available iron for erythropoiesis.
| Original language | English |
|---|---|
| Pages (from-to) | 13-18 |
| Number of pages | 6 |
| Journal | Acta Haematologica |
| Volume | 90 |
| Issue number | 1 |
| Publication status | Published - 1993 |
Fingerprint
Keywords
- Anaemia of renal failure
- Erythropoiesis
- Erythropoietin
- Iron deficiency
- Serum ferritin
- Serum transferrin receptor
ASJC Scopus subject areas
- Hematology
Cite this
Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end-stage renal disease. / Barosi, G.; Merlo, C.; Palestra, P.; Liberato, N. L.; Guarnone, R.; Di Dio, F.; Piazza, V.; Salvadeo, A.
In: Acta Haematologica, Vol. 90, No. 1, 1993, p. 13-18.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Variations in erythropoiesis and serum ferritin during erythropoietin therapy for anaemia of end-stage renal disease
AU - Barosi, G.
AU - Merlo, C.
AU - Palestra, P.
AU - Liberato, N. L.
AU - Guarnone, R.
AU - Di Dio, F.
AU - Piazza, V.
AU - Salvadeo, A.
PY - 1993
Y1 - 1993
N2 - In order to study the relationship between erythropoiesis and serum ferritin (SF) during erythropoietin (rHuEPO) therapy in the anaemia of end-stage renal disease (ESRD), 19 patients were followed without iron supplementation and at a fixed dose of the drug (40 U/kg). Twelve patients failed to attain the target haemoglobin (Hb) value, 7 of whom due to the appearance of iron deficiency. Erythropoiesis, as measured by the serum transferrin receptor concentration, increased from 12 to 120% of the basal value. This increment was not constantly associated with a proportional rise of Hb or reticulocyte count. SF decreased exponentially from a median value of 221 μg/dl (range 42-470) to a median value of 54 μg/dl (range 20-172). Halving of the basal SF value (SF-T50) was reached at the 18th-95th day of therapy (median = 43), representing a iron shift of 3.4-11.6 mg/day (median = 5.4). SF-T50 was not correlated with the Hb increase, but with that of erythropoiesis (r = 0.78; p = 0.003). The minimum SF (MSF) value attained was not correlated with the appearance of iron deficiency. The conclusion is that the rate of SF decrease during rHuEPO in ESRD is a reliable measure of iron mobilisation for erythropoiesis, but not for haematologic response. The MSF value reached during therapy is not representative of available iron for erythropoiesis.
AB - In order to study the relationship between erythropoiesis and serum ferritin (SF) during erythropoietin (rHuEPO) therapy in the anaemia of end-stage renal disease (ESRD), 19 patients were followed without iron supplementation and at a fixed dose of the drug (40 U/kg). Twelve patients failed to attain the target haemoglobin (Hb) value, 7 of whom due to the appearance of iron deficiency. Erythropoiesis, as measured by the serum transferrin receptor concentration, increased from 12 to 120% of the basal value. This increment was not constantly associated with a proportional rise of Hb or reticulocyte count. SF decreased exponentially from a median value of 221 μg/dl (range 42-470) to a median value of 54 μg/dl (range 20-172). Halving of the basal SF value (SF-T50) was reached at the 18th-95th day of therapy (median = 43), representing a iron shift of 3.4-11.6 mg/day (median = 5.4). SF-T50 was not correlated with the Hb increase, but with that of erythropoiesis (r = 0.78; p = 0.003). The minimum SF (MSF) value attained was not correlated with the appearance of iron deficiency. The conclusion is that the rate of SF decrease during rHuEPO in ESRD is a reliable measure of iron mobilisation for erythropoiesis, but not for haematologic response. The MSF value reached during therapy is not representative of available iron for erythropoiesis.
KW - Anaemia of renal failure
KW - Erythropoiesis
KW - Erythropoietin
KW - Iron deficiency
KW - Serum ferritin
KW - Serum transferrin receptor
UR - http://www.scopus.com/inward/record.url?scp=0027372905&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027372905&partnerID=8YFLogxK
M3 - Article
C2 - 8237268
AN - SCOPUS:0027372905
VL - 90
SP - 13
EP - 18
JO - Acta Haematologica
JF - Acta Haematologica
SN - 0001-5792
IS - 1
ER -